GO:0070419 nonhomologous end joining complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070419 (nonhomologous end joining complex) is a cellular component defined as a protein complex that repairs DNA double-strand breaks via nonhomologous end joining (NHEJ), typically containing a specialized DNA ligase such as Lig4 and one or more DNA-end-binding proteins.
• The core NHEJ machinery includes the Ku70/Ku80 heterodimer, DNA-PKcs, XRCC4, XLF, Lig4, and accessory factors that fine-tune end processing and ligation.
• NHEJ is the dominant double-strand break repair pathway in mammalian cells and is active throughout the cell cycle, making it a central target in cancer therapy and genome editing.
• Recent work shows that NHEJ uses distinct mechanisms to repair each strand of a double-strand break, revealing unexpected asymmetry in the ligation step.
• Dysregulation of NHEJ complex components is linked to cancer, immunodeficiency, and neurodegeneration, and NHEJ factors are key determinants of CRISPR-Cas9 editing outcomes.
• Studying GO:0070419 requires integrated approaches including knockout/knock-in cell models, proteomics, imaging, and CRISPR library screening to dissect complex assembly and function.
Description
The nonhomologous end joining complex (GO:0070419) is a multi-protein assembly that repairs DNA double-strand breaks (DSBs) by directly ligating broken DNA ends without a homologous template. This complex is essential for maintaining genome integrity, particularly in post-mitotic cells and during the G1 phase of the cell cycle when homologous recombination is unavailable. The QuickGO definition describes it as a protein complex that plays a role in DNA double-strand break repair via nonhomologous end joining, typically containing a specialized DNA ligase (e.g., Lig4 in eukaryotes) and one or more proteins that bind to DNA ends. Researchers study this complex because its components are frequently mutated or dysregulated in human diseases, and because NHEJ activity directly influences the outcomes of CRISPR-Cas9 genome editing. Understanding the structure, assembly, and regulation of the NHEJ complex is therefore critical for both basic DNA repair biology and therapeutic development.
nonhomologous end joining complex At A Glance
| GO ID | GO:0070419 |
|---|---|
| GO term | nonhomologous end joining complex |
| Ontology | cellular_component |
| Synonym | NHEJ complex, non-homologous end joining complex |
| Major function | Repair of DNA double-strand breaks via nonhomologous end joining, typically involving a specialized DNA ligase (e.g., Lig4) and DNA-end-binding proteins |
| Key components | Ku70/Ku80 heterodimer, DNA-PKcs, XRCC4, XLF, Lig4, and accessory factors |
| Cellular context | Nucleus; active throughout the cell cycle, dominant in G1 |
| Related process | Nonhomologous end joining (NHEJ) |
What Is GO:0070419?
GO:0070419, the nonhomologous end joining complex, is a cellular component defined by its role in repairing DNA double-strand breaks through nonhomologous end joining. This complex typically includes a specialized DNA ligase, such as Lig4 in eukaryotes, along with one or more proteins that bind to DNA ends to protect and process them before ligation. The complex functions without a homologous DNA template, making it distinct from homologous recombination machinery.
Why Is nonhomologous end joining complex Important in Cell Biology?
The nonhomologous end joining complex is vital because it is the primary mechanism for repairing DNA double-strand breaks in mammalian cells, and its dysfunction leads to genomic instability, cancer predisposition, and immunodeficiency. Moreover, NHEJ activity determines the efficiency and accuracy of CRISPR-Cas9 gene editing, making it a central consideration for researchers developing gene therapies.
• Maintains genome integrity by repairing DSBs, especially in post-mitotic cells.
• Its dysregulation is associated with cancer, immunodeficiency, and neurodegeneration.
• Determines the outcomes of CRISPR-Cas9 editing, including knockouts and knock-ins.
• Provides targets for cancer therapy, such as DNA-PKcs inhibitors.
• Involved in V(D)J recombination, essential for adaptive immunity.
• Accessory factors fine-tune NHEJ efficiency and accuracy.
• NHEJ complex assembly is a dynamic process that can be studied with purified systems.
• Recent evidence shows strand-specific repair mechanisms within the complex.
Core Biology of GO:0070419
What Happens During nonhomologous end joining complex?
In simple terms: The NHEJ complex grabs broken DNA ends, holds them together, and stitches them back, even if the ends are not identical.
The nonhomologous end joining complex mediates the repair of DNA double-strand breaks by a multi-step process. First, the Ku70/Ku80 heterodimer rapidly binds to DNA ends, forming a ring that protects the ends and recruits other factors. Next, DNA-PKcs is recruited to the Ku-DNA complex, forming the DNA-PK holoenzyme, which facilitates synapsis of the two DNA ends. End processing by factors such as Artemis, polynucleotide kinase/phosphatase (PNKP), and polymerases (Pol μ, Pol λ) may occur to make ends ligatable. Finally, the XRCC4-Lig4 complex, often with XLF, catalyzes the ligation step. Recent work has revealed that NHEJ uses distinct mechanisms to repair each strand of a double-strand break, indicating asymmetry in the ligation process.
Structure and Composition of nonhomologous end joining complex
In simple terms: The NHEJ complex is built from several proteins that assemble in a specific order on broken DNA ends.
The core NHEJ complex comprises the Ku70/Ku80 heterodimer, DNA-PKcs, XRCC4, XLF, and DNA ligase IV (Lig4). Ku70/Ku80 forms a ring that threads onto DNA ends, serving as the initial damage sensor. DNA-PKcs interacts with the Ku-DNA complex to form the active DNA-PK holoenzyme. XRCC4 and XLF form filaments that stabilize and align the DNA ends, while Lig4 catalyzes phosphodiester bond formation. Accessory factors such as PAXX, MRI, and Artemis further modulate complex assembly and function. The complex is dynamic, with post-translational modifications regulating its assembly and disassembly.
Molecular Mechanism of nonhomologous end joining complex
In simple terms: The complex uses energy from ATP to bring ends together and ligate them, with help from processing enzymes.
The molecular mechanism of NHEJ involves ATP-dependent DNA-PKcs activation, which promotes end synapsis and phosphorylation of downstream targets. Lig4 uses ATP to form a covalent enzyme-AMP intermediate, then transfers AMP to the 5'-phosphate of the DNA end, activating it for ligation. XRCC4 stimulates Lig4 activity, while XLF promotes ligation of incompatible ends. End processing by nucleases and polymerases ensures that damaged or non-ligatable ends are modified before ligation. Recent studies show that nucleosomal substrates can be repaired by NHEJ in purified systems, indicating that chromatin context influences the mechanism.
Regulation of nonhomologous end joining complex
In simple terms: The complex is turned on and off by chemical modifications and protein interactions to ensure repair happens at the right time and place.
NHEJ complex activity is regulated by post-translational modifications, including phosphorylation, acetylation, and methylation. For example, methylation of Ku70 by SMYD2 affects its stability and NHEJ repair capacity. DNA-PKcs autophosphorylation regulates its kinase activity and complex disassembly. Accessory factors such as PAXX and MRI fine-tune NHEJ efficiency and accuracy in a context-dependent manner. Additionally, cell cycle-dependent expression and localization of NHEJ components ensure that repair is coordinated with DNA replication and cell division.
Key Genes Involved in GO:0070419 nonhomologous end joining complex
The following genes encode core and accessory components of the nonhomologous end joining complex (GO:0070419) and are frequently studied in DNA repair research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| XRCC6 (Ku70) | DNA end binding, heterodimer with Ku80 | Knockout leads to NHEJ deficiency and radiosensitivity |
| XRCC5 (Ku80) | DNA end binding, heterodimer with Ku70 | Essential for Ku complex formation and NHEJ |
| PRKDC (DNA-PKcs) | Catalytic subunit of DNA-PK, kinase activity | Target for cancer therapy and radiosensitization |
| LIG4 | DNA ligase IV, catalyzes ligation | Mutations cause LIG4 syndrome and immunodeficiency |
| XRCC4 | Stimulates Lig4, stabilizes complex | Defects lead to growth retardation and radiosensitivity |
| NHEJ1 (XLF) | Promotes ligation of incompatible ends | Mutations linked to immunodeficiency and radiosensitivity |
| PAXX | Accessory factor, stabilizes Ku-DNA complex | Modulates NHEJ efficiency |
| MRI (CYREN) | Accessory factor, inhibits NHEJ in specific contexts | Regulates NHEJ during cell cycle |
| DCLRE1C (Artemis) | Nuclease for end processing | Mutations cause severe combined immunodeficiency |
| POLM (Pol μ) | Polymerase for gap filling | Contributes to NHEJ flexibility |
| POLL (Pol λ) | Polymerase for gap filling | Important for NHEJ of damaged ends |
| PNKP | Kinase/phosphatase for end cleaning | Required for ligatable ends |
| APLF | Accessory factor, interacts with XRCC4 | Modulates NHEJ and chromatin binding |
| SMYD2 | Methyltransferase that methylates Ku70 | Inhibition impairs NHEJ and antitumor immunity |
| ATM | Kinase that coordinates DSB repair | Regulates NHEJ choice and cell cycle checkpoints |
| TP53BP1 | Scaffold protein that promotes NHEJ | Determines repair pathway choice |
| RIF1 | Effector of 53BP1, promotes NHEJ | Inhibits end resection and favors NHEJ |
| SHLD1/2/3 | Shieldin complex, protects DNA ends | Promotes NHEJ and antagonizes resection |
How Is nonhomologous end joining complex Regulated?
The nonhomologous end joining complex is regulated at multiple levels, including post-translational modifications, protein-protein interactions, and cell cycle-dependent expression. Phosphorylation by DNA-PKcs and ATM modulates complex assembly and disassembly. Methylation of Ku70 by SMYD2 affects its stability and NHEJ capacity, linking epigenetic regulation to repair efficiency. Accessory factors such as PAXX and MRI fine-tune NHEJ activity in a context-dependent manner. Additionally, the choice between NHEJ and homologous recombination is influenced by end resection, which is regulated by 53BP1, RIF1, and the Shieldin complex.
nonhomologous end joining complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LIG4 | LIG4 syndrome, immunodeficiency | Knockout cell lines, patient-derived iPSCs |
| DCLRE1C | Severe combined immunodeficiency (SCID) | Knockout mice, patient fibroblasts |
| XRCC4 | Growth retardation, radiosensitivity | Knockout cell lines, knock-in of patient mutations |
| SMYD2 | Cancer, impaired antitumor immunity | Knockout or inhibitor-treated cancer cells |
| TP53BP1 | Cancer, defective DNA repair | Knockout cell lines, xenograft models |
Cancer and NHEJ Dysregulation
Altered expression or mutation of NHEJ complex components is frequently observed in cancers. For example, SMYD2-mediated methylation of Ku70 impairs NHEJ and affects antitumor immunity, suggesting that targeting this axis could enhance immunotherapy. DNA-PKcs overexpression is associated with poor prognosis in several cancers, and inhibitors are in clinical trials. Defects in NHEJ can also lead to genomic instability that drives tumorigenesis.
Immunodeficiency and NHEJ Defects
Mutations in NHEJ genes such as LIG4, XRCC4, and DCLRE1C (Artemis) cause severe combined immunodeficiency (SCID) due to defective V(D)J recombination, which relies on NHEJ. These patients present with radiosensitivity, growth retardation, and recurrent infections. Understanding the molecular basis of these disorders informs diagnostic and therapeutic strategies.
Neurodegeneration and DNA Repair
Neurons are particularly vulnerable to DNA double-strand breaks due to their post-mitotic nature and high metabolic activity. Defects in NHEJ have been linked to neurodegenerative diseases such as ataxia telangiectasia and Alzheimer's disease. The NHEJ complex is critical for maintaining neuronal genome integrity, and its dysfunction may contribute to age-related cognitive decline.
From nonhomologous end joining complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X affect NHEJ efficiency? | Knockout cell line (e.g., HEK293T, U2OS) |
| Does a point mutation in LIG4 alter ligation activity? | Point-mutation knock-in cell line |
| How does a tag affect complex assembly? | Tagged knock-in (e.g., GFP, FLAG) |
| Does overexpression of DNA-PKcs increase radioresistance? | Overexpression cell line |
| Which genes are synthetic lethal with NHEJ defects? | CRISPR library screening |
| How does SMYD2 inhibition affect Ku70 methylation? | Knockout or inhibitor-treated cells |
How to Study the nonhomologous end joining complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality and synthetic lethality | Identify novel NHEJ regulators |
| AP-MS | Protein-protein interactions | Map NHEJ complex composition |
| Live-cell imaging | Real-time recruitment and dynamics | Visualize complex assembly at DSBs |
| In vitro ligation assay | Ligation efficiency and accuracy | Dissect minimal NHEJ requirements |
| Western blot | Protein expression and modifications | Assess Ku70 methylation or DNA-PKcs phosphorylation |
| Comet assay | DNA damage and repair kinetics | Measure NHEJ capacity in cells |
| Reporter assays | NHEJ efficiency in vivo | Screen for inhibitors or activators |
| ChIP-seq | Genome-wide binding of NHEJ factors | Map repair sites and chromatin context |
CRISPR-Cas9 Knockout Screens
Genome-wide CRISPR knockout screens can identify genes that modulate NHEJ activity. For example, screens using reporters of DSB repair have uncovered novel accessory factors that fine-tune the NHEJ machinery. These screens are powerful for discovering synthetic lethal interactions and resistance mechanisms.
Proteomics and Interactomics
Affinity purification coupled with mass spectrometry (AP-MS) can map the composition and dynamics of the NHEJ complex. Studies using purified systems have revealed how nucleosomal substrates are repaired by NHEJ components. Proteomic approaches also identify post-translational modifications that regulate complex assembly.
Imaging and Live-Cell Analysis
Live-cell imaging of fluorescently tagged NHEJ proteins (e.g., Ku70-GFP, Lig4-RFP) allows real-time visualization of complex assembly at DNA damage sites. This approach has shown that NHEJ factors are recruited sequentially and that repair occurs with distinct kinetics for each strand.
Biochemical Reconstitution
In vitro reconstitution with purified proteins is used to dissect the molecular mechanism of NHEJ. For example, purified Ku, DNA-PKcs, XRCC4-Lig4, and XLF can ligate defined DNA substrates, revealing the minimal requirements for end joining. Such systems allow precise manipulation of reaction conditions and components.
How CRISPR Can Be Used to Study GO:0070419 nonhomologous end joining complex
Knockout
CRISPR-Cas9 knockout of core NHEJ genes such as LIG4, XRCC4, or PRKDC creates cell models with defective NHEJ, which are valuable for studying DNA repair mechanisms and for sensitizing cancer cells to radiation or chemotherapy. These models also help identify synthetic lethal interactions.
Point Mutation
Introducing patient-derived point mutations (e.g., in LIG4 or XRCC4) via CRISPR knock-in allows researchers to study the functional impact of specific amino acid changes on NHEJ activity and complex assembly. Such models are crucial for understanding genotype-phenotype relationships in NHEJ-related diseases.
Knock-in
Tagged knock-in of NHEJ genes (e.g., GFP or FLAG tags) enables real-time imaging and biochemical purification of the complex from endogenous loci, preserving physiological expression levels. This approach is ideal for studying complex dynamics and interactions.
Overexpression
Overexpression of NHEJ components such as DNA-PKcs or Lig4 can be used to study gain-of-function effects, including increased radioresistance or altered repair fidelity. Overexpression models are also useful for testing inhibitors and for structural studies.
How EDITGENE Supports nonhomologous end joining complex Research
Researchers studying nonhomologous end joining complex-related genes often need to determine whether a candidate gene is causally involved in DNA repair, whether a specific mutation alters complex assembly, or whether overexpression changes cellular radiosensitivity. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for nonhomologous end joining complex research.
Frequently Asked Questions About nonhomologous end joining complex
What is the nonhomologous end joining complex?
The nonhomologous end joining complex (GO:0070419) is a protein assembly that repairs DNA double-strand breaks by directly ligating broken ends without a homologous template, typically containing Lig4 and DNA-end-binding proteins.
What genes are involved in the nonhomologous end joining complex?
Core genes include XRCC6 (Ku70), XRCC5 (Ku80), PRKDC (DNA-PKcs), LIG4, XRCC4, and NHEJ1 (XLF), along with accessory factors such as PAXX, MRI, and DCLRE1C (Artemis).
How does the nonhomologous end joining complex work?
Ku70/Ku80 binds DNA ends, recruits DNA-PKcs, and together with XRCC4-Lig4 and XLF, processes and ligates the ends in an ATP-dependent manner.
What diseases are associated with defects in the nonhomologous end joining complex?
Defects cause immunodeficiency (e.g., LIG4 syndrome, SCID), cancer predisposition, and neurodegeneration.
How is the nonhomologous end joining complex regulated?
It is regulated by phosphorylation, methylation (e.g., SMYD2-mediated Ku70 methylation), and accessory factors that fine-tune activity.
What methods are used to study the nonhomologous end joining complex?
Common methods include CRISPR knockout screens, AP-MS, live-cell imaging, in vitro ligation assays, and comet assays.
Can CRISPR be used to model NHEJ defects?
Yes, CRISPR knockout or knock-in of NHEJ genes creates isogenic cell models to study repair deficiency and test therapeutics.
What is the role of DNA-PKcs in the nonhomologous end joining complex?
DNA-PKcs is the catalytic subunit of DNA-PK that, upon binding to Ku-DNA, activates kinase activity and promotes end synapsis and processing.
How does the nonhomologous end joining complex affect CRISPR editing?
NHEJ determines the efficiency of CRISPR-Cas9 knockout and knock-in outcomes, as it repairs the Cas9-induced double-strand break.
What are the latest findings on the nonhomologous end joining complex?
Recent studies show that NHEJ uses distinct mechanisms to repair each strand of a double-strand break and that nucleosomal substrates can be repaired in purified systems.
Conclusion
The nonhomologous end joining complex (GO:0070419) is a cornerstone of genome maintenance, with essential roles in DNA double-strand break repair, immune diversity, and CRISPR-based genome editing. Its dysfunction underlies a spectrum of human diseases, from immunodeficiency to cancer, making it a prime target for therapeutic intervention. Continued research using advanced CRISPR models and multi-omics approaches will further illuminate its mechanisms and translational potential.
References
- 1. Luthman AJ et al.. 2025. Nonhomologous end-joining uses distinct mechanisms to repair each strand of a double strand break.. Nat Commun 16(1):11599 PMID: 41285786
- 2. Ghosh D et al.. 2021. Nonhomologous end joining: new accessory factors fine tune the machinery.. Trends Genet 37(6):582-599 PMID: 33785198
- 3. Tang M et al.. 2023. SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity.. Sci Adv 9(24):eade6624 PMID: 37315132
- 4. Waters CA et al.. 2014. Nonhomologous end joining: a good solution for bad ends.. DNA Repair (Amst) 17:39-51 PMID: 24630899
- 5. Stinson BM et al.. 2021. Repair of DNA Double-Strand Breaks by the Nonhomologous End Joining Pathway.. Annu Rev Biochem 90:137-164 PMID: 33556282
- 6. Gerodimos CA et al.. 2021. Nonhomologous DNA end joining of nucleosomal substrates in a purified system.. DNA Repair (Amst) 106:103193 PMID: 34339948
- 7. Ceccaldi R et al.. 2025. Mechanisms and regulation of DNA end resection in the maintenance of genome stability.. Nat Rev Mol Cell Biol 26(8):586-599 PMID: 40133633
- 8. Pannunzio NR et al.. 2018. Nonhomologous DNA end-joining for repair of DNA double-strand breaks.. J Biol Chem 293(27):10512-10523 PMID: 29247009
